SkinBioTherapeutics (LSE:SBTX), an AIM-listed UK life sciences company focused on skin health and microbiome-driven technologies, has appointed industry executive Rachel Parsonage as interim chief executive officer for an initial six-month period. Her appointment includes a planned position on the board, subject to standard regulatory approvals. The company develops cosmetic skincare products through its SkinBiotix platform and gut–skin health supplements under the AxisBiotix brand, while collaborating with Croda on the Zenakine active ingredient and expanding its capabilities through acquisitions that enhance manufacturing and distribution.
Executive chairman Martin Hunt said Parsonage’s experience in business turnaround and stakeholder engagement will support efforts to stabilise operations, oversee an ongoing forensic review into current business issues and reposition the group for renewed growth. Management expects the leadership transition to help restore operational focus and rebuild momentum as the company seeks to accelerate commercial progress.
SkinBioTherapeutics’ outlook remains shaped largely by financial challenges, including ongoing losses and negative cash flow, alongside a pronounced technical downtrend reflected in share price performance below major moving averages and negative MACD indicators. Strong revenue growth and a relatively conservative balance sheet provide some offset, though valuation remains constrained by a lack of profitability and the absence of dividend support.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life sciences company specialising in skin health technologies built around its proprietary SkinBiotix platform, originally developed in collaboration with the University of Manchester. The company targets the skin healthcare market through cosmetic skincare products, gut–skin axis nutritional supplements and related dermatological applications.
Leave a Reply